The impact of statin treatment on diabetic patients.
Retrospective analysis of secondary prevention trials indicates that 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors (statins) reduce the risk of recurrent coronary heart disease events in individuals with diabetes. Diabetic individuals may receive greater benefit from statin treatment than non-diabetic individuals, because of a higher absolute risk. Available data are limited, although several randomized trials of primary prevention with diabetic patients are ongoing. The low-density lipoprotein cholesterol goal is now considered to be < 100 mg/dl for individuals with diabetes. Pleiotropic effects of statins may be involved in anti-atherogenic or other actions of statin.
Koshiyama
Hiroyuki
H
Division of Diabetes & Endocrinology, Department of Internal Medicine, Medical Institute Kitano Hospital, 2-4-20 Ohgi-machi, Kita-ku, Osaka 530-0025, Japan. h-koshiyama@kitano-hp.or.jp
D008078:Cholesterol, LDL / Q000097:blood; D003327:Coronary Disease / Q000150:complications* / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000453:epidemiology; D004730:Endothelium, Vascular / Q000187:drug effects; D006801:Humans; D006903:Hydroxymethylglutaryl CoA Reductases / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D012307:Risk Factors; D020521:Stroke / Q000517:prevention & control
D008078:Cholesterol, LDL; D006903:Hydroxymethylglutaryl CoA Reductases